A world-first study in today's New England Journal of Medicine heralds the efficacy of a targeted combination drug therapy after reporting major declines in the risk of disease progression and death in people with metastatic ...
Sep 29, 2014
0
0
Yale Cancer Center (YCC) scientists have found that combining the targeted drug trastuzumab with chemotherapy significantly improves survival rates for women with a rare, aggressive form of endometrial cancer. These results ...
Jun 29, 2020
0
2
Epithelioid sarcoma, a rare aggressive cancer that usually strikes young adults, and rhabdoid tumors, which affect children, have long been difficult to treat. But the outlook for people with these subtypes of soft tissue ...
Feb 5, 2024
0
9
Researchers at the University of Wisconsin–Madison and Academia Sinica of Taiwan have harnessed a combination of lab-grown cells to regenerate damaged heart muscle.
Oct 31, 2023
0
0
Each year, more than 25,000 Americans are diagnosed with multiple myeloma, a form of blood cancer that often develops resistance to therapies. However, researchers at Virginia Commonwealth University Massey Cancer Center ...
May 1, 2014
0
0
(HealthDay)—Patients receiving immune checkpoint inhibitor (ICI) regimens may experience endocrine dysfunction, with increased risk of thyroid dysfunction and hypophysitis for patients on combination therapy, according ...
Sep 29, 2017
0
1
After surgeons removed the tumor from her breast last November, Karen Hajiaskari, of Hamburg, N.Y., was deemed cancer-free. But for the next five years she will take a drug called tamoxifen, a medication that's commonly used ...
Oct 7, 2012
0
0
(HealthDay)—Ted Adamson's liver had been so ravaged by the hepatitis C virus that he was nearly at the point of needing a liver transplant. Yet he had no symptoms. None. He didn't even feel tired.
Dec 21, 2012
0
0
Supervised exercise combined with a procedure that opens clogged blood vessels reduces leg pain significantly better than exercise alone in patients with blocked blood vessels in the legs, according to a late-breaking clinical ...
Nov 19, 2013
0
0
Combination targeted adjuvant therapy with dabrafenib and trametinib doubles relapse-free survival in patients with stage III BRAF-mutant melanoma, according to late-breaking results from the COMBI-AD trial presented today ...
Sep 11, 2017
0
0
